Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial We analyzed ...
Despite the successful application of adoptive T-cell transfer with chimeric antigen receptor (CAR)-engineered T cells for the treatment of various hematologic malignancies, several other hematologic ...
Adoptive cell therapies (ACT) have become a transformative force in cancer immunology, offering powerful platforms for targeting both hematological and ...
Adoptive Cell Transfer (ACT) includes a class of immunotherapy approaches to treat cancer. This procedure focuses on a special type of immune cell called T cells. These cells, particularly the subset ...
Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) have partnered on a new award, the ICRF-CRI Immunotherapy Collaborative Project Grant, given to Dr. Asaf Madi, PhD, of Tel ...
Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...
Immune checkpoint inhibitors (ICIs) have reshaped modern oncology, yet many solid tumors remain challenging to treat because of limited antigen visibility, extensive genetic heterogeneity, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results